721880-65-5Relevant articles and documents
CHEMICAL COMPOUNDS
-
Page/Page column 44; 55, (2018/10/19)
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.
Design of selective Cathepsin inhibitors
Bethel, Paul A.,Gerhardt, Stefan,Jones, Emma V.,Kenny, Peter W.,Karoutchi, Galith I.,Morley, Andrew D.,Oldham, Keith,Rankine, Neil,Augustin, Martin,Krapp, Stephan,Simader, Hannes,Steinbacher, Stefan
scheme or table, p. 4622 - 4625 (2010/04/29)
A number of molecular recognition features have been exploited in structure-based design of selective Cathepsin inhibitors.